ARTICLE | Clinical News
Lifitegrast: Phase III started
January 14, 2013 8:00 AM UTC
SARcode began the double-blind, placebo-controlled, U.S. Phase III OPUS-2 trial to evaluate twice-daily 5% lifitegrast for 12 weeks in about 700 patients with dry eye disease who have used artificial ...